Get started
Viking Therapeutics, Inc.Viking Therapeutics, Inc.Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Discussions Forecast Seasonals

1VT chart


Full chart

1VT upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.59 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.305 EUR
Net income (FY)
‪−106.22 M‬ EUR
Revenue (FY)
0.00 EUR
Shares float
‪109.09 M‬
Beta (1Y)
1.28

Employees


Employees (FY)
36
Change (1Y)
+9 +33.33%
Revenue / Employee (1Y)
—
Net income / Employee (1Y)
—

About Viking Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Brian Lian
Website
vikingtherapeutics.com
Headquarters
San Diego
Founded
2012
ISIN
US92686J1060
FIGI
BBG008MYSTS9
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Check out other big names from the same industry as 1VT.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

1VT news



Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Viking Therapeutics, Inc. stocks are traded under the ticker 1VT.
We've gathered analysts' opinions on Viking Therapeutics, Inc. future price: according to them, 1VT price has a max estimate of 106.71 EUR and a min estimate of 28.17 EUR. Watch 1VT chart and read a more detailed Viking Therapeutics, Inc. stock forecast: see what analysts think of Viking Therapeutics, Inc. and suggest that you do with its stocks.
1VT reached its all-time high on Feb 28, 2024 with the price of 91.500 EUR, and its all-time low was 0.770 EUR and was reached on Aug 3, 2017. View more price dynamics on 1VT chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track Viking Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Viking Therapeutics, Inc. is going to release the next earnings report on Oct 22, 2025. Keep track of upcoming events with our Earnings Calendar.
1VT earnings for the last quarter are −0.49 EUR per share, whereas the estimation was −0.38 EUR resulting in a −29.90% surprise. The estimated earnings for the next quarter are −0.60 EUR per share. See more details about Viking Therapeutics, Inc. earnings.
Viking Therapeutics, Inc. revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
1VT net income for the last quarter is ‪−55.65 M‬ EUR, while the quarter before that showed ‪−42.18 M‬ EUR of net income which accounts for −31.96% change. Track more Viking Therapeutics, Inc. financial stats to get the full picture.
No, 1VT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 9, 2025, the company has 36 employees. See our rating of the largest employees — is Viking Therapeutics, Inc. on this list?
Like other stocks, 1VT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Viking Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.